Shire Adderall XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryOnce-daily formulation of the company's attention deficit hyperactivity disorder therapy Adderall (mixed salts of a single entity amphetamine product) is "approvable" Aug. 3. The company expects to receive approval by the end of the year
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.